Tirzepatide vs NAD+ (Nicotinamide Adenine Dinucleotide)
Head-to-head comparison of Tirzepatide and NAD+ (Nicotinamide Adenine Dinucleotide) for research applications. Both peptides are studied for Metabolic Health, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Tirzepatide | Nad Plus |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Anti-Aging / Telomere |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. | Functions as: (1) an electron carrier in glycolysis, TCA cycle, and oxidative phosphorylation; (2) a substrate for sirtuins (SIRT1-7), which regulate gene expression, DNA repair, and metabolism; (3) a substrate for PARPs, which repair DNA damage; (4) a substrate for CD38/CD157, involved in calcium signaling and immune function. |
| Evidence Rating | A — FDA Approved | C — Early Human / Mixed Evidence |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | NAD+ IV: used clinically at anti-aging and addiction clinics; no FDA approval. NMN: Phase I/II human trials completed (Yoshino et al., Science 2021). NR: multiple human trials completed. |
| Safety Profile | Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems; FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath | IV NAD+: commonly causes flushing, nausea, chest tightness, abdominal cramping during infusion — dose-rate dependent; Rare tachycardia and blood pressure changes during IV infusion |
| Molecular Weight | ~4813.5 g/mol | 663.43 g/mol |
| Half-Life | ~5 days (116 hours) | ~30 minutes (IV plasma); intracellular NAD+ turnover ~6-10 hours |
Overview
Tirzepatide and NAD+ (Nicotinamide Adenine Dinucleotide) are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Tirzepatide — Mechanism & Evidence
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.
Key claims: Superior weight loss compared to semaglutide; Improves blood sugar control; May improve liver fat / NASH.
Tirzepatide 10mg
10mg
Tirzepatide 30mg
30mg
NAD+ (Nicotinamide Adenine Dinucleotide) — Mechanism & Evidence
NAD+ is a fundamental coenzyme present in all living cells that serves as a critical electron carrier in metabolic reactions and a substrate for enzymes including sirtuins, PARPs, and CD38. NAD+ levels decline approximately 50% between ages 40 and 60. While not a peptide, NAD+ and its precursors (NMN, NR) are frequently discussed in peptide communities. IV NAD+ infusions are popular at anti-aging clinics, though large-scale human efficacy trials are limited.
Key claims: IV NAD+ restores youthful cellular function; NAD+ precursors (NMN/NR) slow aging; Helps with addiction and withdrawal.
Shared Research Applications
Both peptides are studied for: Metabolic Health.
Tirzepatide is also researched for: Weight Management.
NAD+ (Nicotinamide Adenine Dinucleotide) is also researched for: Anti-Aging & Longevity.
Safety Considerations
Tirzepatide: Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath Immunogenicity: 51% developed antibodies with no observed effect on efficacy
NAD+ (Nicotinamide Adenine Dinucleotide): IV NAD+: commonly causes flushing, nausea, chest tightness, abdominal cramping during infusion — dose-rate dependent Rare tachycardia and blood pressure changes during IV infusion Theoretical concern: NAD+ is used by cancer cells; boosting NAD+ in the presence of occult malignancy could promote tumor progression
Shop Research Peptides
Tirzepatide 10mg
10mg
Tirzepatide 30mg
30mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tirzepatide vs Retatrutide: Evidence, Mechanisms, Safety
This reference distinguishes randomized trial evidence from extrapolation for tirzepatide and retatrutide, clarifying mechanisms and safety. It highlights the absence of direct head-to-head trials and the limits of current data.
Tirzepatide Tied to Reduced Heart Attack Risk in High-Risk Patients
A recent report highlights that the GLP-1 drug tirzepatide is associated with a lower risk of heart attacks in patients considered high-risk. The finding adds to growing evidence of cardiovascular benefits for this class of medications. Details from the WDBJ7 report are summarized here.
Tirzepatide News: GLP-1 Drug Demand Surges, MACE Risk May Drop
Recent reports suggest tirzepatide, a GLP-1 drug, may reduce MACE risk in high-risk patients while demand for injectable GLP-1 therapies remains strong. This analysis covers the latest tirzepatide news and its implications for peptide research and clinical practice.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe